Antiviral Medications for Treatment and Prophylaxis of Influenza
| Age Group (Years) | |||
|---|---|---|---|
| Antiviral Drug | Children (≤12) | 13-64 | ≥65 |
| Oseltamivir | |||
| Treatment, influenza A and B | Age 1-12, dose varies by weighta | 75 mg PO bid | 75 mg PO bid |
| Prophylaxis, influenza A and B | Age 1-12, dose varies by weightb | 75 mg PO qd | 75 mg PO qd |
| Zanamivir | |||
| Treatment, influenza A and B | Age 7-12, 10 mg bid by inhalation | 10 mg bid by inhalation | 10 mg bid by inhalation |
| Prophylaxis, influenza A and B | Age 5-12, 10 mg qd by inhalation | 10 mg qd by inhalation | 10 mg qd by inhalation |
| Amantadinec | |||
| Treatment, influenza A | Age 1-9, 5 mg/kg in 2 divided doses, up to 150 mg/d | Age ≥10, 100 mg PO bid | ≤100 mg/d |
| Prophylaxis, influenza A | Age 1-9, 5 mg/kg in 2 divided doses, up to 150 mg/d | Age ≥10, 100 mg PO bid | ≤100 mg/d |
| Rimantadinec | |||
| Treatment, influenza A | Not approved | 100 mg PO bid | 100-200 mg/d |
| Prophylaxis, influenza A | Age 1-9, 5 mg/kg in 2 divided doses, up to 150 mg/d | Age ≥10, 100 mg PO bid | 100-200 mg/d |
a<15 kg: 30 mg bid; >15-23 kg: 45 mg bid; >23-40 kg: 60 mg bid; >40 kg: 75 mg bid. For children <1 year of age, see www.cdc.gov/h1n1flu/recommendations.htm.
b<15 kg: 30 mg qd; >15-23 kg: 45 mg qd; >23-40 kg: 60 mg qd; >40 kg: 75 mg qd. For children <1 year of age, see www.cdc.gov/h1n1flu/recommendations.htm.
c Amantadine and rimantadine are not currently recommended (2013-2014) because of widespread resistance in influenza A viruses. Their use may be reconsidered if viral susceptibility is reestablished.